CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
NAFLD-specific weight loss intervention +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04186260
NCT04186260N/ACompleted
CompareCT.gov

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

University of Arizona·interventional·Posted Dec 4, 2019·Updated Aug 24, 2025

In Brief

A clinical study evaluating NAFLD-specific weight loss intervention and Wait-list control for NAFLD. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Using a small Randomized Controlled Trial (RCT) study design, PNPLA3 risk allele carriers (CG/GG genotype) with NAFLD, will be assigned 2:1 to a tailored NAFLD-specific weight loss intervention compared to a wait-list control group.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNAFLD
CountriesUnited States
CollaboratorsNational Institute on Minority Health and Health Disparities (NIMHD)

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedDec 4, 2019
Enrollment StartFeb 5, 2024
Primary CompletionMay 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.6 years ago

Interventions

NAFLD-specific weight loss interventionbehavioral

This is a 12-month NAFLD-specific weight loss intervention that is explicitly tailored for Mexican-American men. It will include recommendations for diet, physical activity, and will utilize risk for NAFLD as a mechanism to engage men in lifestyle modification.

Wait-list controlother

Participants in this condition will not receive treatment for 12-months until study comparisons have been made. After 12-months, participants will receive the 12-month NAFLD-specific weight loss intervention.